Similarly, Comin et al. [85] found thrombomodulin expression in almost all histology of lung cancer (from 71% in squamous cell carcinomas to 4% in lung adenocarcinoma), while calretinin immunoreactivity was evidenced in 44% of small cell lung carcinomas, 25% of large cell neuroendocrine carcinomas, 20% of squamous cell carcinomas, 10% of sarcomatoid carcinomas, and 4% of adenocarcinomas (4%). The gene discussed is THBD; the disease is adenocarcinoma.